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Rational drug designObjectives/Background: Dihydrofolate reductase (DHFR) is one of the validated drug targets in
Mycobacterium tuberculosis (Mtb) infection. DHFR inhibitors have been used to treat vari-
ous life-threatening diseases such as cancer, malaria, and several bacterial infections. How-
ever, all clinically effective DHFR inhibitors are non-selective, and inhibit both human and
pathogenic DHFRs more or less to a similar extent. The crystal structure of various DHFRs
complexed with nicotinamide adenine dinucleotide phosphate and different inhibitors is
available in the protein data bank. The crystal structures are validated and have been used
for new drug designing. M. tuberculosis DHFRs and human (h) DHFRs show 26% structure
similarity, but their active sites are not identical and this characteristic forms the basis of
this study. Because most of the reported inhibitors of M. tuberculosis DHFR are pteridine
based and nonselective in nature, that is, they inhibit both microbial and host DHFRs, this
study aimed to design and develop selective nonpteridine M. tuberculosis DHFR inhibitors.
Method: In the ternary complex of methotrexate with M. tuberculosis DHFR, whose struc-
ture is also available in the protein data bank, the side of the aminopterin ring is accessible
to the solvent; additionally, a glycerol ‘‘A” molecule is found in a depression nearby. This
glycerol molecule interacts with the side chains of Trp22, Asp27, and Gln28, which form a
pocket in M. tuberculosis DHFR; by contrast, glycerol is absent in h-DHFR. In the h-DHFRs
(complexed with folate or N-(4-carboxy-{-[(2, 4-diamino pteridine-6-yl methyl)-amino]-
benzoyl amino} -butyl) pthalamic acid (COP)), the site is well packedwith three hydrophobic
residue side chains, Leu22, Pro26, and Phe31, which correspond to Leu20, Arg23, and Gln28,
respectively, found in M. tuberculosis DHFR. Therefore, compounds with side chain, which
could mimic the binding mode of glycerol to protein, may bind to M. tuberculosis DHFR
selectively. Such a derivative should be sterically and chemically hindered from forming a
complex with h-DHFR. This assumption forms the basis of this study and this understand-
ing has been used for designing selective inhibitors of M. tuberculosis DHFR.
Results: A number of novel nonpteridine-based molecules have been identified after the vir-
tual screening of three databases (MDPI, NCI and inhouse databases). The best molecules
identified after screening the three databases have been synthesized and tested for antitu-
bercular activity. The results are promising and require further work in this direction.
Conclusion: Structure based drug design can be used as an effective tool for the design of
new cheiocal entity. Number of novel agents have been identified as antitubercular agents
whose mechanism of action needs to be ascertained..
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